Guest Editor(s)

• Prof. Jörg Kleeff

  Department of Surgery, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany.

  Website | E-mail

Special Issue Introduction

Pancreatic ductal adenocarcinoma (PDAC) is one of the most challenging human cancers and is predicted to become the second most common cause of cancer-related deaths in the United States by 2030. Radical surgery combined with neoadjuvant/ adjuvant therapy is currently the only option to cure pancreatic cancer patients. However, only a small subset of patients has resectable tumors at the time of diagnosis, often due to metastasis or invasion of the adjacent vasculature. Further, extensive heterogeneity and substantial crosstalk within the tumor microenvironment are involved in therapeutic resistance. Recent advances in the understanding of molecular characteristics of pancreatic tumor development, tumor and stromal heterogeneity can lead to advances in the treatment of pancreatic cancer patients. The current special issue will highlight the recent key findings in the field of pancreatic cancer research and new strategies to improve the therapy for this disease.

Topics of interest include, but are not limited to:
• Molecular mechanisms of pancreatic cancer development
• Signaling pathways involved in carcinogenesis
• The role of the immune system and immune modulators
• Genetic and epigenetic aberrations in pancreatic cancer
• Tumor and stromal heterogeneity in pancreatic cancer
• Targeted therapies and novel combination therapies
• Advances in clinical care for pancreatic cancer patients

Participants

1. Timothy Pawlik The Ohio State University, Columbus, OH, USA
2. Núria Malats Centro Nacional de Investigaciones Oncológicas, Madrid, Spain.
3. Laura D Wood Department of Pathology and The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
4. Per Pfeiffer and Mathilde Weisz Ejlsmark Department of Oncology, Odense University Hospital, Odense C, Denmark.
5. Véronique Orian-Rousseau Institute of Biological and Chemical Systems−Functional Molecular Systems, Karlsruhe Institute of Technology, Germany.
6. Michael Muders Rudolf-Becker-Laboratory for Prostate Cancer Research, Institute of Pathology, University of Bonn Medical Center, Bonn, Germany.
7. Savio G Barreto Flinders University, Adelaide, Australia.
8. Riitta Lassila and Hanna Seppänen Helsinki University Hospital, Helsinki, Finland.
9. Rebekah White and Suna Erdem University of California, San Diego, CA, USA.
10. John W. Kunstman Yale School of Medicine, New Haven, IN, USA.
11. Alfredo Carrato and Julie Earl Biomedical Research Networking Centre on Cancer (CIBERONC), Madrid, Spain.
12. Marco Falasca Curtin University, Perth, Australia.
13. Bart Rose and Brendon R Herring The University of Alabama at Birmingham, Birmingham, AL, USA.
14. Qi Chen University of Kansas Medical Center, Kansas, KS, USA.
15. Ramakrishnan Elancheran Annamalai University, Chidambaram, India.
16. Victor Hugo Fonseca de Jesus A.C.Camargo Cancer Center, Sao Paulo, Brazil.
17. Manish Bhandare Shailesh Shrikhande and Vikram Chaudhari; Tata Memorial Hospital, Mumbai, India.
18. Wasif Saif and Diane Barker Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
19. Margaret Tempero School of Medicine, University of California, San Francisco, San Francisco, CA, USA.
20. Hari K. Koul and Karnika Singh Stanley S Scott Cancer Center, School of Medicine, LSU Health Sciences Center – New Orleans, LA, USA.
21. Anne Noonan The Ohio State University Wexner Medical Center, Columbus, IN, USA.
22. Yi Miao Pancreas Research Institute, Nanjing Medical University, Nanjing, China.
23. Melissa Fishel Indiana University-Purdue University Indianapolis, Indianapolis, IN, USA.
24. Xiaoyan Qiu Peking University, Beijing, China.
25. Francesco Novelli Università degli Studi di Torino, Turin, Italy.
26. Fabio Grizzi Humanitas University, Pieve Emanuele, Italy.
27. Likang Sun Tianjin University of Traditional Chinese Medicine, Tianjin, China.
The list is arranged in no particular order and being updated.

Submission Deadline

31 Jan 2021

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jcmtjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/JCMT/?IssueId=467
Submission Deadline: 31 Jan 2021
Contacts: Gladys Di, Assistant Editor, gladys@jcmtjournal.com